A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Zhao, Hongyun
Zhang, Zhonghan
Luo, Fan
Ma, Yuxiang
Fang, Wenfeng
Yang, Yunpeng
Zhang, Yang
Huang, Yan
Zhang, Li
机构：
[1] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS9116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9116
引用
收藏
页数：2
相关论文
共 50 条
  • [31] TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)
    Quoix, Elisabeth A.
    Nemunaitis, John J.
    Burzykowski, Tomasz
    Bastien, Berangere
    Lacoste, Gisele
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] DAILY ORAL PERIFOSINE IN COMBINATION WITH RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: FIRST RESULTS OF A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE II STUDY
    Verheij, M.
    Karchmit, Y.
    Bakardjiev, S.
    Beliaukouski, V.
    Savu, M.
    Smickoska, S.
    Sindermann, H.
    Markivskyy, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S167 - S167
  • [33] Phase II/III clinical trial of randomized, double-blind, placebo-controlled combined with recombinant human endostatin in treatment of advanced non-small cell lung cancer
    Xu Liyan
    Shi He Heling
    Liu Zhe
    Zhu Yunzhong
    Li Baolan
    Zhang Shucai
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S354
  • [34] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Lee, Siow Ming
    Khan, Iftekhar
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Marshall, Ernie
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Chao, David
    Middleton, Gary
    Bulley, Sue
    Ngai, Yenting
    Rudd, Robin
    Hackshaw, Allan
    Boshoff, Chris
    LANCET ONCOLOGY, 2012, 13 (11): : 1161 - 1170
  • [35] Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
    Janne, Pasi A.
    Shaw, Alice Tsang
    Pereira, Jose Rodrigues
    Jeannin, Gaelle
    Vansteenkiste, Johan
    Barrios, Carlos H.
    Franke, Fabio A.
    Grinsted, Lynda
    Smith, Paul D.
    Zazulina, Victoria
    Smith, Ian C.
    Crino, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] GEFITINIB (G) AND PEMETREXED (PEM) AS A FIRST LINE TREATMENT IN PATIENTS WITH EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Yoshimura, N.
    Matsuura, K.
    Mitsuoka, S.
    Asai, K.
    Tochino, Y.
    Kimura, T.
    Nakai, M.
    Mitsukawa, Y.
    Hirata, K.
    Kudoh, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 413
  • [37] Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial
    Zhou, C.
    Ren, S.
    Chen, J.
    Xu, X.
    Cheng, Y.
    Chen, G.
    Pan, Y.
    Fang, Y.
    Wang, Q.
    Huang, Y.
    Yao, W.
    Wang, R.
    Li, X.
    Zhang, W.
    Zhang, Y.
    Hu, S.
    Guo, R.
    Yang, Z.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S748 - S748
  • [38] CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    De Marchi, Pedro
    Goto, Yasushi
    Kowalski, Dariusz M.
    Lu, Shun
    Paz-Ares, Luis G.
    Spigel, David R.
    Spira, Alexander, I
    Thomas, Michael
    Leung, Mimi
    Baum, Jason
    Zhu, Zewen
    Oliveira Portella, Maria do Socorro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of pacilitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC)
    Han, B.
    Xiu, Q.
    Luo, Y.
    Bai, C.
    Guo, S.
    Liu, W.
    Zhuang, Z.
    Zhang, Y.
    Zhou, J.
    Jin, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
    Boyer, Michael
    Hui, Rina
    Urban, Damien
    Clingan, Philip
    Su, Wu-Chou
    Devaux, Celine
    Gadgeel, Shirish
    Garassino, Marina
    Leopold, Lance
    Daniel, Jeannie
    Munteanu, Mihaela C.
    Samkari, Ayman
    Luo, Yiwen
    Abreu, Delvys Rodriguez
    BMC CANCER, 2024, 23 (SUPPL 1)
12345